search

Active clinical trials for "Iron Overload"

Results 41-50 of 153

Efficacy and Safety of Oral Deferasirox (20 mg/kg/d) in Pts 3 to 6 Months After Allogeneic Hematopoietic...

Iron Overload

The purpose of this study is to investigate the effects of iron chelation using deferasirox in patients who show signs of iron overload after an allogeneic stem cell transplantation The iron overload must be due to blood transfusions.

Completed16 enrollment criteria

Extension Study of Iron Chelation Therapy With Deferasirox in Patients With Transfusional Iron Overload...

Transfusional Iron Overload

A 1-year randomized Phase IIa core trial followed by a prolongation of 5 to 9 months was conducted to investigate the efficacy and safety of deferasirox in patients aged ≥ 18 years with transfusion-dependent iron overload. The objective of this extension study is to assess the long-term safety of deferasirox and to provide treatment in patients with transfusional iron overload.

Completed3 enrollment criteria

Safety and Efficacy of Deferasirox in Patients With Transfusion Dependent Iron Overload - a Non-comparative...

Liver Iron Overload

The purpose of this study is to assess the safety and the effects on liver iron of Deferasirox when given for a long treatment period in patients with transfusion dependent iron overload.

Completed10 enrollment criteria

Combination Deferasirox and Deferiprone for Severe Iron Overload in Thalassemia

Thalassemia Major With Severe Transfusional Iron Overload

We hypothesize that the combination treatment with deferasirox and deferiprone will be well tolerated and will result in significant improvement in cardiac and liver iron levels.

Completed15 enrollment criteria

Post Hematopoietic Stem Cell Transplantation

Iron Overload After Hematopoietic Stem Cell Transplantation (HSCT) in Patients With Beta-thalassemia Major

This was a prospective, single-arm, multicenter, national, phase II clinical study. The purpose of this Phase II study was to examine the safety and efficacy of deferasirox to decrease iron overload (IOL) in the posttransplant period in patients with beta-thalassemia major.

Completed10 enrollment criteria

Effects of Phlebotomy on Insulin Sensitivity in Insulin Resistance-associated Hepatic Iron Overload...

Insulin ResistanceIron Overload

The purpose of this study is to evaluate efficacy of phlebotomy on insulin sensitivity as evaluated by euglycemic-hyperinsulinic clamp in insulin resistance-associated hepatic iron overload patients.

Completed25 enrollment criteria

Safety Study of Crushed Deferasirox Film Coated Tablets in Pediatric Patients With Transfusional...

Iron Overload

This study employed a prospective, single-arm, global multi-center interventional open-label, non-randomized design to identify and assess safety profile of the crushed deferasirox FCT when administered up to 24 weeks in pediatric patients aged ≥2 to <6 years with transfusional hemosiderosis. The study was designed to enroll a minimum of 40 patients. Forty-four patients were treated and analyzed.

Completed25 enrollment criteria

Effect of Spirulina Compared to Amlodipine on Cardiac Iron Overload in Children With Beta Thalassemia...

Beta Thalassemia Major

the aim of this study is to evaluate the effect of Spirulina compared to Amlodipine on cardiac iron overload and cardiac functions in multi-transfused children with beta thalassemia major

Completed6 enrollment criteria

Extended Evaluation of Deferasirox Film-coated Tablet (FCT) Formulation

Chronic Iron Overload

Extend evaluation of deferasirox film-coated tablet (FCT) formulation

Completed21 enrollment criteria

Amlodipine in the Prevention and Treatment of Iron Overload in Patients With Thalassemia Major

ThalassemiaIron Overload

This study aims to investigate the use of amlodipine, a drug that blocks the uptake of calcium into cells, in the prevention and treatment of iron overload in patients with thalassemia major. Since iron uses the same calcium channels to enter the heart, pancreas and other organs, blocking these channels might help to prevent the accumulation of iron in these tissues. The study will follow 60 patients with thalassemia major: 30 will receive amlodipine and 30 will serve as controls receiving placebo in a randomized double-blind fashion. Patients will be monitored through one year. Monitoring will occur through the measurement of blood ferritin as well as live and heart T2* by MRI initially, at 6 and 12 months.

Completed7 enrollment criteria
1...456...16

Need Help? Contact our team!


We'll reach out to this number within 24 hrs